Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab

Yi, Ming; Zhang, Linjie; Liu, Xiaojiao; Wang, Nan; Huang, Chen-Na; Liu, Mingqi; Chang, Sheng-Hui; Liu, Wan-Di; Yang, Li

doi:10.1016/j.jocn.2020.11.017

Cited by 5 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…16,17 On the other hand, complement also plays an important role in the pathogenesis of patients with MG. All kinds of complement components can eventually form a complement complex. With the deposition of complement complex on the cell surface, the biological activity of the cell may change due to its stimulation effect, affecting the disease performance of patients with MG 18,19 In this study, after three months of treatment, the experimental group showed more significant changes in AChRab, clinical absolute score, C3 and C4 levels, suggesting that methylprednisolone high-dose pulse therapy and medium-dose periodic therapy of methylprednisolone had similar effects on the improvement of antibody, complement levels and symptom performance in the early treatment of patients with MG. In the long-term treatment, medium-dose periodic therapy boasts a more stable effect.…”

Section: Groupmentioning

confidence: 99%

Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis

Qi²

2022

Pak J Med Sci

View full text Add to dashboard Cite

Objective: To investigate the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis (MG). Methods: A total of 98 patients with MG admitted to Shijiazhuang People’s Hospital from December 2018 to November 2019 were randomly divided into two groups, with 49 cases in each group. Patients in the control group received high-dose methylprednisolone pulse therapy, while those in the experimental group received medium-dose periodic therapy of methylprednisolone. Anti-acetylcholine receptor antibodies (AChRab), clinical absolute scores, complement levels (C3, C4), T lymphocyte subsets (CD3+, CD4+, CD4+CD25+), cytokines [interferon-γ (INF-γ), transforming growth factor-β1 (TGF-β1), interleukin-6 (IL- 6), interleukin-18 (IL-18)], and changes in quality of life [15-item Myasthenia Gravis Quality of Life Scale (MGQOL-15) score] were compared between the two groups before treatment and one and three months after treatment. Moreover, the incidence of adverse drug reactions in the two groups during 3 months of treatment was compared. Results: After three months of treatment, ACHRAB, clinical absolute score, CD3+, CD4+, INF-γ, IL-6, IL-18 and MGQOL-15 scores in both groups were significantly decreased compared with those before treatment (p<0.05), and the scores of C3, C4, CD4+CD25+ and TGF-β1 in both groups were significantly higher than those before treatment (p<0.05), and the experimental group had more significant changes than the control group (p<0.05). During three months of treatment, the total incidence of adverse drug reactions in the experimental group was significantly lower than that in the control group (p<0.05). Conclusions: The medium-dose periodic therapy of methylprednisolone is more prominent in the long-term efficacy performance. It can improve the immunity and quality of life of patients, and it is safer and has high clinical application value. doi: https://doi.org/10.12669/pjms.38.4.5069 How to cite this:Lin X, Qi G. Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis. Pak J Med Sci. 2022;38(4):---------. doi: https://doi.org/10.12669/pjms.38.4.5069 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

show abstract

Section: Groupmentioning

confidence: 99%

Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis

Qi²

2022

Pak J Med Sci

View full text Add to dashboard Cite

show abstract

“…IL-6 is associated with MG severity in AChR+ MG patients and the use of anti-IL-6 therapy, like tocilizumab, causes a decreased level of IL-6 [57]. IL-33, proliferation-inducing ligand, IL-19, IL-20, IL-28A, IL-35, IL-27, and IL-36γ are other novel biomarkers that are increased in MG patients [58][59][60]. In addition, other inflammatory proteins increase in MG and could be used as biomarkers alongside other specific MG biomarkers: metalloproteinase 10, transforming growth factor-α (TGFα), S100 Ca 2+ -binding protein A12 (S100A12), IL-6, IL-8, C-C motif ligand 19, and C-X-C motif ligand 1 [61].…”

Section: Immunologic Biomarkers Of Mgmentioning

confidence: 99%

Overview of biomarkers in myasthenia gravis

Afrashteh

Rajabi

2022

Explor Neuroprot Ther

View full text Add to dashboard Cite

Myasthenia gravis (MG) is a rare auto-immune neuromuscular junction (NMJ) disorder which is caused by formation of autoantibodies and destruction of NMJ components. The MG diagnosis is based on the symptoms, autoantibodies detection and paraclinical tests. Given that MG patients have so many differential diagnosis and various medication responses, choosing an accurate diagnosis and the therapy plan in MG is challenging. According to the studies, there are the immunologic, genetic, microRNAs, gut microbiome, and other established or newly proposed biomarkers for diagnosis and prognosis of MG. More studies are needed to provide better collection of biomarkers in MG patients and evaluate their role in MG pathology.

show abstract

“…IL-27, on the other hand, has been found to activate multiple signaling cascades that promote/inhibit different TH cell activation and thus produce opposite immune effects, respectively ( 9 ). Also, IL-27 is associated with neurological pathologies, including myasthenia gravis, Guillain-Barre syndrome, and ischemia-reperfusion, and may even play a neuroprotective role in reducing neuroinflammation ( 10 – 12 ).…”

Section: Introductionmentioning

confidence: 99%

Gut microbiota linked to hydrocephalus through inflammatory factors: a Mendelian randomization study

Shen,

Li,

Zhang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundThe gut microbiota (GM) has been implicated in neurological disorders, but the relationship with hydrocephalus, especially the underlying mechanistic pathways, is unclear. Using Mendelian randomization (MR), we aim to discover the mediating role of inflammatory factors in the relationship between GM and hydrocephalus.MethodsAfter removing confounders, univariable and multivariable MR analyses were performed using summary statistics to assess the causal relationships between GM, inflammatory factors (IL-17A and IL-27), and types of hydrocephalus. Meta-analyses were used to reconcile the differences in MR results between different hydrocephalus sources. Finally, mediator MR analyses were applied to determine the mediating effect of inflammatory factors. Various sensitivity analysis methods were employed to ensure the reliability and stability of the results.ResultsAfter correction for P-values, Firmicutes (phylum) (OR, 0.34; 95%CI, 0.17–0.69; P = 2.71E-03, PFDR = 2.44E-02) significantly reduced the risk of obstructive hydrocephalus. The remaining 18 different taxa of GM had potential causal relationships for different types of hydrocephalus. In addition, Firmicutes (phylum) decreased the risk of obstructive hydrocephalus by increasing levels of IL-17A (mediating effect = 21.01%), while Eubacterium ruminantium group (genus) increased the risk of normal-pressure hydrocephalus by decreasing levels of IL-27 (mediating effect = 7.48%).ConclusionWe reveal the connection between GM, inflammatory factors (IL-17A and IL-27), and hydrocephalus, which lays the foundation for unraveling the mechanism between GM and hydrocephalus.

show abstract

Increased serum IL-27 concentrations and IL-27-producing cells in MG patients with positive AChR-Ab

Cited by 5 publications

References 26 publications

Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis

Observation on the efficacy of different methylprednisolone regimens in the treatment of myasthenia gravis

Overview of biomarkers in myasthenia gravis

Gut microbiota linked to hydrocephalus through inflammatory factors: a Mendelian randomization study

Contact Info

Product

Resources

About